H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 48 Citations 8,496 76 World Ranking 2944 National Ranking 1389

Overview

What is he best known for?

The fields of study he is best known for:

  • Antibody
  • Gene
  • Immune system

Richard M. Scearce spends much of his time researching Virology, Antibody, Epitope, Molecular biology and Monoclonal antibody. The study incorporates disciplines such as Immunogen, Immunology and Immunogenicity in addition to Virology. He has researched Antibody in several fields, including Immune system, Glycoprotein and Vaccination.

His Vaccination research incorporates themes from Mutation and Neutralization. His Epitope study frequently involves adjacent topics like Virus. His Neutralizing antibody study combines topics from a wide range of disciplines, such as T cell, B cell and Antigen.

His most cited work include:

  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (776 citations)
  • Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus (776 citations)
  • Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies (651 citations)

What are the main themes of his work throughout his whole career to date?

Richard M. Scearce mostly deals with Antibody, Virology, Molecular biology, Monoclonal antibody and Epitope. Richard M. Scearce has included themes like T cell, Antigen and Vaccination in his Antibody study. Richard M. Scearce mostly deals with Virus in his studies of Virology.

His Molecular biology research is multidisciplinary, incorporating perspectives in Receptor, breakpoint cluster region, Ligand, Protein structure and Naive B cell. His Monoclonal antibody research integrates issues from Epithelium, Western blot, Cellular differentiation and Glycoprotein. His study explores the link between Epitope and topics such as Peptide sequence that cross with problems in Amino acid.

He most often published in these fields:

  • Antibody (71.58%)
  • Virology (62.11%)
  • Molecular biology (43.16%)

What were the highlights of his more recent work (between 2016-2021)?

  • Antibody (71.58%)
  • Virology (62.11%)
  • Immunization (11.58%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Antibody, Virology, Immunization, Vaccination and Recombinant DNA. The Antibody study combines topics in areas such as Molecular biology, Naive B cell and Immune system. His Virology research is multidisciplinary, relying on both Immunology, Glycan, Epitope and Immunogen, Monoclonal antibody.

The various areas that Richard M. Scearce examines in his Epitope study include Immunoglobulin heavy chain, Glutamic acid and Aspartic acid. He studied Vaccination and HIV vaccine that intersect with Viremia, Immunogenicity, Vaccine trial and Simian immunodeficiency virus. His Neutralizing antibody research is multidisciplinary, incorporating elements of Antigen and Affinity maturation.

Between 2016 and 2021, his most popular works were:

  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination (367 citations)
  • Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. (113 citations)
  • Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (79 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Antibody
  • Immune system

Antibody, Virology, Immunization, Vaccination and Immunogen are his primary areas of study. His Antibody research includes elements of Molecular biology, Binding site and Antigen. The Molecular biology study combines topics in areas such as T cell, Immune system, Affinity maturation and Germinal center, B cell.

His studies in Binding site integrate themes in fields like HIV vaccine and Heterologous. His work on Viral Vaccine as part of general Vaccination study is frequently linked to Pandemic, bridging the gap between disciplines. His Immunogen research incorporates themes from Recombinant DNA, Pentavalent vaccine, Antibody-dependent cell-mediated cytotoxicity, Vaccine efficacy and Serology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies

Barton F. Haynes;Judith Fleming;E. William St. Clair;Herman Katinger.
Science (2005)

989 Citations

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Hua-Xin Liao;Rebecca Lynch;Tongqing Zhou;Feng Gao;Feng Gao.
Nature (2013)

847 Citations

The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes

S. Munir Alam;Mildred McAdams;David Boren;Michael Rak.
Journal of Immunology (2007)

351 Citations

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Norbert Pardi;Michael J. Hogan;Rebecca S. Pelc;Hiromi Muramatsu.
Nature (2017)

337 Citations

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein

Feng Gao;Eric A. Weaver;Zhongjing Lu;Yingying Li.
Journal of Virology (2005)

310 Citations

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Hua Xin Liao;Laura L. Sutherland;Shi Mao Xia;Mary E. Brock.
Virology (2006)

303 Citations

Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

T J Palker;T J Matthews;A Langlois;M E Tanner.
Journal of Immunology (1989)

192 Citations

Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

S. Munir Alam;Richard M. Scearce;Robert J. Parks;Kelly Plonk.
Journal of Virology (2008)

189 Citations

Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment.

B F Haynes;R M Scearce;D F Lobach;L L Hensley.
Journal of Experimental Medicine (1984)

175 Citations

Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.

T J Palker;M E Tanner;R M Scearce;R D Streilein.
Journal of Immunology (1989)

158 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Richard M. Scearce

Barton F. Haynes

Barton F. Haynes

Duke University

Publications: 342

David C. Montefiori

David C. Montefiori

Duke University

Publications: 201

John R. Mascola

John R. Mascola

National Institutes of Health

Publications: 124

Georgia D. Tomaras

Georgia D. Tomaras

Duke University

Publications: 123

Hua-Xin Liao

Hua-Xin Liao

Jinan University

Publications: 120

Dennis R. Burton

Dennis R. Burton

Scripps Research Institute

Publications: 114

Lynn Morris

Lynn Morris

University of the Witwatersrand

Publications: 94

S. Munir Alam

S. Munir Alam

Duke University

Publications: 93

Peter D. Kwong

Peter D. Kwong

National Institutes of Health

Publications: 87

Andrew B. Ward

Andrew B. Ward

Scripps Research Institute

Publications: 86

Bette T. Korber

Bette T. Korber

Los Alamos National Laboratory

Publications: 86

Michael S. Seaman

Michael S. Seaman

Beth Israel Deaconess Medical Center

Publications: 83

Michel C. Nussenzweig

Michel C. Nussenzweig

Rockefeller University

Publications: 82

Celia C. LaBranche

Celia C. LaBranche

Duke University

Publications: 81

M. Anthony Moody

M. Anthony Moody

Duke University

Publications: 80

Rogier W. Sanders

Rogier W. Sanders

University of Amsterdam

Publications: 76

Something went wrong. Please try again later.